IgA Nephropathy Drugs Market to Reach 12.26 billion by 2032

IgA Nephropathy Drugs Market 

The Global IgA Nephropathy Drugs Market was valued at approximately USD 0.94 billion in 2025 and is projected to reach approximately USD 12.26 billion by 2032, supported by rising diagnosis, broader use of disease-specific therapies and a growing focus on preserving kidney function in patients with persistent proteinuria and progression risk.

IgA nephropathy, also known as Berger disease, is a chronic immune-mediated kidney disorder that can lead to progressive kidney damage, declining eGFR and eventual kidney failure. The disease often affects younger adults and can remain underdiagnosed for years because definitive diagnosis commonly depends on kidney biopsy. Recent U.S. epidemiological estimates place the number of people living with IgAN at approximately 198,887–208,184, with annual incidence of around 1.9–2.2 cases per 100,000 people.

The commercial landscape has changed quickly. Six disease-specific therapies currently hold FDA approval for IgAN in the United States: Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact and Trutakna. Their availability has shifted treatment away from a market dominated mainly by supportive kidney care and selected corticosteroid use toward a broader specialty-nephrology category.

Proteinuria and eGFR have become central clinical measures in this transition. Persistent proteinuria remains an important marker of progression risk and is widely used to assess treatment response, while long-term preservation of kidney function is becoming increasingly important in regulatory, prescribing and reimbursement decisions. Voyxact, for example, received FDA approval following data showing an approximately 50% reduction in proteinuria at nine months in adults with biopsy-confirmed IgAN, while longer-term renal outcomes remain important for confirming durable clinical value.

Commercial uptake of established therapies already shows that IgAN can support meaningful specialty-drug revenue. Filspari generated approximately USD 322 million in U.S. net product sales in 2025, compared with USD 132.2 million in 2024, while Travere reported 908 new patient start forms in the fourth quarter of 2025. Tarpeyo generated approximately USD 323 million in U.S. sales during fiscal 2025, confirming sustained physician adoption in a relatively concentrated patient population.

Fabhalta has also emerged as an important renal specialty product. Novartis reported approximately USD 505 million in worldwide Fabhalta sales in 2025 across its approved indications. Although this figure is not specific to IgAN, it highlights the commercial potential of therapies positioned within high-value renal and immune-mediated disease categories.

Regional opportunity differs significantly. The United States remains the most commercially mature IgAN market, supported by a broader approved treatment portfolio and higher specialty-drug revenue per treated patient. China represents one of the largest patient-volume opportunities, with disease-specific access improving through regulatory approvals and national reimbursement. Europe has a sizeable but fragmented patient base, where uptake varies by country because of reimbursement and health-technology assessment. Japan also has a substantial diagnosed population, with a 2026 nationwide study estimating approximately 103,800 patients, including around 15,646 with high disease activity.

The pipeline remains active despite the growing number of marketed therapies. Povetacicept, zigakibart and felzartamab are among the most closely watched late-stage candidates, while additional complement and immune-directed programs continue to progress through clinical development. Their future role will depend on whether they can establish durable kidney-function benefit, acceptable safety and clear positioning within an increasingly competitive treatment pathway.

Treatment cost is another important market factor. Several newer IgAN medicines carry annual U.S. treatment costs well above USD 100,000, with some products reaching several hundred thousand dollars per year. This pricing environment increases the importance of patient selection, reimbursement, treatment persistence and evidence showing that short-term proteinuria reduction translates into longer-term kidney preservation.

The economic burden of IgAN rises considerably as patients progress through chronic kidney disease. Advanced cases require more intensive nephrology care and may eventually lead to dialysis or transplantation. This places increasing emphasis on therapies that can delay kidney-function decline and reduce the long-term clinical burden associated with kidney failure.

The main unmet need is also evolving. IgAN is no longer defined simply by a lack of disease-specific treatment. The more pressing challenges are earlier diagnosis, identification of patients at highest risk, clearer treatment sequencing, durable preservation of eGFR, long-term treatment persistence and affordability.

As more therapies enter the market, competition is expected to shift from availability alone toward clinical durability and real-world positioning. Products that demonstrate sustained kidney protection, achieve broad reimbursement and remain practical for long-term use are likely to be best placed as the diagnosed and treatment-eligible population expands through 2032.